COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation and Treatment of Tall Statured Girls (TallgirlsDK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02638922
Recruitment Status : Unknown
Verified April 2016 by Anders Juul, Rigshospitalet, Denmark.
Recruitment status was:  Active, not recruiting
First Posted : December 23, 2015
Last Update Posted : April 6, 2016
Information provided by (Responsible Party):
Anders Juul, Rigshospitalet, Denmark

Brief Summary:


To evaluate the phenotypic characteristics and diagnoses in a large cohort of 304 consecutive girls referred due to tall stature. Furthermore, to evaluate the effect of oral administration of 17β-estradiol on predicted adult height in constitutionally tall statured girls.


A single-centre retrospective observational study of 304 girls evaluated due to tall stature between 1993 and 2013.


Tertiary referral centre for pediatric endocrinology.


A total of 304 girls were evaluated for tall stature of whom 39 (13%) were excluded due to missing data, reclassification, overgrowth syndromes or associated comorbidities. Another 58 (19%) girls did not fulfil auxological criteria for constitutionally tall stature (CTS), resulting in a total of 207 (68%) girls eligible for analysis.

Main Outcome Measures

The effect of oral treatment with 17β-estradiol on height, predicted adult height (PAH), final height and circulating hormones in constitutional tall statured girls.

Condition or disease Intervention/treatment
Constitutional Tall Stature Drug: Estradiol

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 304 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Evaluation of 304 Danish Girls With Tall Stature: Phenotypic Characteristics and Effects of Oral Administration of Natural 17β-Estradiol
Study Start Date : January 2014
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Group/Cohort Intervention/treatment
no treatment
girls who never received estradiol treatment
Estradiol treatment
girls who received estradiol treatment
Drug: Estradiol
Estradiol containing compounds administered orally in a non-randomized manner.
Other Names:
  • Estradiol (Trisekvens®, Novo Nordisk, Denmark),
  • Estradiol (Trisekvens Forte®, Novo Nordisk, Denmark)
  • Estradiol (Femanest®, Sandoz A/S, Denmark)

Primary Outcome Measures :
  1. final height [ Time Frame: 10 year observation time ]
    attainment of final height

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients registered in our tertiary referral centre included

Inclusion Criteria:

  • tall stature (height > 2 SD)

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02638922

Sponsors and Collaborators
Rigshospitalet, Denmark
Layout table for investigator information
Principal Investigator: Anders Juul, MD Rigshospitalet, Denmark
Principal Investigator: Emmie Upners, student Rigshospitalet, Denmark
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Anders Juul, Professor, Rigshospitalet, Denmark Identifier: NCT02638922    
Other Study ID Numbers: RH-2015-218-04161
First Posted: December 23, 2015    Key Record Dates
Last Update Posted: April 6, 2016
Last Verified: April 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Polyestradiol phosphate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic